NASDAQ · CJMB

Callan JMB Inc.

$2.70 +$0.15 (+5.88%) 1D Pre-market

Key Metrics

$14.40M
Market cap
P/E · TTM
$5.38M
Revenue · TTM
−$9.94M
Net income
EPS · TTM $-1.82
Dividend yield
Free cash flow −$5.30M
Beta · 1Y 0.59
EBITDA · TTM −$9.80M
Gross margin 35.6%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    The stock moved +39.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 23
  • Jul 17
    The stock moved +41.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 17
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 15
    From its Feb 2 high, the share price fell 67%.

    Peak close $2.11 on Feb 2; trough close $0.70 on Jun 15. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -67%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$14.40M
Enterprise value
Shares outstanding5.6M
52-wk range$0.65 – $5.61
Avg volume · 20D1.0M
Net cash
Book value / share$0.29
IndustryServices-Business Services, Nec
ExchangeNASDAQ
About Callan JMB Inc.
IPO dateFeb 5, 2025
Employees20

Callan Jmb Inc is a vertically integrated logistics and fulfillment company that provides cryogenic logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology, and specialized cold chain logistics know-how.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.68
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 35.6%
Operating -184.9%
Net -184.8%
FCF -98.6%
ROE / ROIC -416.6% · -5,403.6%

Financial Health

Current ratio2.00
Quick ratio1.86
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.52M

Cash Flow · TTM

Operating CF −$4.66M
Capex −$637.21K
Free cash flow −$5.30M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-5.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings